December 13, 2018
Antoine Yver, Global Head of Oncology, Daiichi Sankyo Daiichi Sankyo is “contemplating” the filing of a US biologics license application (BLA) for its flagship HER2-targeting antibody drug conjugate (ADC) DS-8201 (trastuzumab deruxtecan) in the first half of FY2019, the company’s...read more